Investigators reported the development of LCatlas, a point-of-care web application available at https://www.lcatlas.org. The tool accepts nine routinely available variables to generate a prediction of clinical benefit to first-line immunotherapy or to immunotherapy plus chemotherapy in non-small cell lung cancer. The inputs are gender, smoking history, presence of bone/pleura/liver metastasis, PDL1 tumor staining, albumin level, hemoglobin level, lymphocyte count, neutrophil count, and platelet count. The authors noted that these features were extracted from electronic medical records and selected to enable bedside use with minimal additional testing.
The study team used retrospective data from a development cohort of 79 NSCLC patients who had received first-line immune checkpoint inhibitors. The authors extracted demographic, clinical, and molecular features from chart review. The source did not report additional detail in the abstract about patient-level demographics, histologic subtypes, lines of therapy beyond first-line, or how missing data were handled; those specifics were not provided in the abstract text.
Investigators compared three independent modeling approaches: a statistical model (logistic regression), a machine-learning method (XGBoost), and an AI model (TabTransformer). The study team observed differences across approaches and selected the best-performing model to power the web application. The abstract did not enumerate hyperparameters, feature-engineering steps, or the exact process by which the final model was chosen beyond stating that these three approaches were compared.
Using internal cross-validation on the development cohort, the authors reported an area under the receiver-operating-characteristic curve (AUC) of 79% with a confidence interval of 72%–85%. They reported sensitivity of 87% (72%–95%) and specificity of 78% (64%–89%). The investigators stated that LCatlas performed favorably against previous studies, including some high-volume, deep-learning approaches, although the abstract did not supply head-to-head comparative data or references within the summary text.
The study team evaluated LCatlas in an independent validation cohort consisting of 28 individuals. In that external cohort, the authors reported a prediction accuracy of 82%. The abstract did not supply further breakdowns such as calibration, positive predictive value, negative predictive value, time-to-event outcomes, or subgroup performance by PDL1 strata.
Authors confirmed institutional oversight: access to patient records was approved by the University of Southern California Institutional Review Board (IRB HS-15-00200). Given the retrospective nature of the work, informed consent was waived, the authors noted. The web application and data/code links were made publicly available by the team; the preprint lists the application URL and points to supplementary material and code resources. The abstract did not indicate any prospective registry entries for a validation trial, nor did it claim regulatory clearance for clinical use.
Several coauthors reported multiple industry relationships, including consulting and institutional research funding; other authors declared no conflicts. The preprint clearly states that the manuscript has not been certified by peer review and that findings should not be used to guide clinical practice until further validation and review.
The authors presented performance metrics from a development cohort of 79 patients and an independent validation cohort of 28 patients; those cohort sizes are relatively small for broad generalizability, the study team acknowledged implicitly by providing the sample counts. The abstract did not report granular demographic breakdowns, external multicenter testing, or prospective clinical utility testing. The model-development methods reported in the abstract did not include details on missing-data handling, model hyperparameters, or per-variable importance, so readers cannot fully evaluate reproducibility from the abstract alone. Finally, because the work appears as a medRxiv preprint, peer review and independent replication remain necessary next steps before clinical deployment. Specific unanswered questions that remain and that the source did not report include prospective performance in diverse clinical settings, comparative effectiveness versus established biomarkers in randomized designs, and potential impact on treatment selection and patient outcomes.